1 Min Read
April 26 (Reuters) - Zoetis Inc
* Zoetis receives european commission marketing authorization for Cytopoint® (lokivetmab) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.